ReviewFrontiers in pharmacology2021
Natural-Derived Polysaccharides From Plants, Mushrooms, and Seaweeds for the Treatment of Inflammatory Bowel Disease.
Review in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Harmonized Metagenomic Signatures of the Gut Microbiome Reveal Robust Species, Functions, and Strain Links to Inflammatory Bowel Disease.Gastroenterology · 2026Article
- Multi-modal therapeutic approaches to inflammatory bowel disease: plant-derived compounds, nanoparticle drug delivery systems, and gene-based interventions.Molecular biology reports · 2026Review
- A next-generation probiotic strain for gut health: Bacteroides cellulosilyticus LYH2 variant with anti-inflammatory and metabolic advantages.EBioMedicine · 2026Article
- Dual-pathway mechanisms of plant-derived polysaccharides in ulcerative colitis: integrative roles of microbiota modulation, immune regulation, and barrier restoration.Frontiers in pharmacology · 2026Review
- Digestive properties in fermentation driven interactions of plant polysaccharides with gut microbiota and their health implications.Frontiers in pharmacology · 2026Review
- Insights into biosynthesis, regulation, and functional potentials of exopolysaccharide from Leptolyngbya sp. MKU-05.World journal of microbiology & biotechnology · 2025Article
- Research Advances in the Impact of Probiotic Supplementation on Ulcerative Colitis Management.Nutrients · 2025Review
- Chemical Characterization and In Vitro Antioxidant, Anti-Inflammatory, and Colon Cancer-Preventive Potential of a Polysaccharide Fraction fromInternational journal of molecular sciences · 2025Article
- Article
- Polysaccharides with Arabinose: Key Players in Reducing Chronic Inflammation and Enhancing Immune Health in Aging.Molecules (Basel, Switzerland) · 2025Review
- Mushrooms as Nutritional Powerhouses: A Review of Their Bioactive Compounds, Health Benefits, and Value-Added Products.Foods (Basel, Switzerland) · 2025Review
- Effects of choline metabolite-trimethylamine N-oxide on immunometabolism in inflammatory bowel disease.Frontiers in immunology · 2025Review
- Marine-Derived Fucose-Containing Carbohydrates: Review of Sources, Structure, and Beneficial Effects on Gastrointestinal Health.Foods (Basel, Switzerland) · 2024Review
- Review
- Polysaccharides derived from golden mushroom (Frontiers in pharmacology · 2024Article
- The Potential Effect of Polysaccharides Extracted from Red AlgaPharmaceuticals (Basel, Switzerland) · 2023Article
- An Immunomodulatory Polysaccharide-Protein Complex Isolated from the Polypore FungusJournal of fungi (Basel, Switzerland) · 2023Article
- Potential of natural flavonols and flavanones in the treatment of ulcerative colitis.Frontiers in pharmacology · 2023Review
- Preparation of Highly Substituted Sulfated Alfalfa Polysaccharides and Evaluation of Their Biological Activity.Foods (Basel, Switzerland) · 2022Article
- Pectic polysaccharides ameliorate the pathology of ulcerative colitis in mice by reducing pyroptosis.Annals of translational medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD) is a chronic inflammatory disease impairing the gastrointestinal tract, and its incidence and prevalence have been increasing over time worldwide. IBD greatly reduces peoples' quality of life and results in several life-threatening complications, including polyp, toxic colonic dilatation, intestinal perforation, gastrointestinal bleeding, and cancerization. The current therapies for IBD mainly include drugs for noncritical patients and operation for critical patients. However, continuous use of these drugs causes serious side effects and increased drug resistance, and the demand of effective and affordable drugs with minimal side effects for IBD sufferers is urgent. Natural-derived polysaccharides are becoming a research hotspot for their therapeutic effects on IBD. This study focuses on the research progress of various natural polysaccharides from plants, seaweeds, and mushrooms for the treatment of IBD during recent 20 years. Regulation of oxidative stress, inflammatory status, gut microbiota, and immune system and protection of the intestinal epithelial barrier function are the underlying mechanisms for the natural-derived polysaccharides to treat IBD. The excellent efficacy and safety of polysaccharides make them promising candidates for IBD therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.